N-(4-Fluorophenyl)-N'-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide, 95.0%, 25g

Methyl 6-O-(N-heptylcarbamoyl)-a-D-glucopyranoside, 99.0%, 250mg

Rimonabant>98.0%(HPLC)100mg

4-(3-(Trifluoromethyl)pyridin-2-yl)benzaldehyde, 98+%, 1g

N-METHYL-N-[(3S)-PYRROLIDIN-3-YL]METHANESULFONAMIDE HCL, 95.0%, 500mg

Methyl 3,4-dihydro-2H-1,4-benzoxazine-7-carboxylate, 95.0%, 5g

1-((tetrahydro-2H-pyran-4-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 95.0%, 5g

cis-1,4-Dimethylcyclohexane>98.0%(GC)25mL

(1S,2S)-N1,N2-Bis(3,3-dimethylbutyl)-N1,N2-dimethylcyclohexane-1,2-diamine, 95.0%, 1g

4-((2,2,10,10-Tetramethyl-4,8-dioxo-3,9-dioxa-5,7-diazaundecan-6-ylidene)amino)butanoic acid, 97%, 100mg

Infinity corrected plan PL 20x/0.40 IOS objective. Working distance 1.5 mm

(9-Acetoxy-3-ethyl-8,8,10,10-tetramethyl-1,5-dioxa-9-azaspiro[5.5]undecan-3-yl)methyl stearate, 100mg

Glycyl-DL-norvaline>97.0%(HPLC)(T)5g